Platelet AbnormalityNCT06948630
Hemogram Parameter Changes With Sepsis Filter
An observational study of Platelet Abnormality and Renal Failure, run by Samsun University at 1 site in Turkey (Türkiye).
Trial summary
Hemodiafiltration is initiated in hemodynamically unstable patients in intensive care units. In some patients, additional devices called cytokine filters or sepsis filters are added to remove inflammatory cytokines. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Platelet Abnormality, Renal Failure, Immune System Disorder
- How many people
- 92 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Jan 2024to 1 Feb 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Hemodiafiltration is started on patients in intensive care units. This study focuses on the change in hemogram rates in patients who underwent hemofiltration and had sepsis filters placed.
Who may be able to join
- Data of patients who were monitored in the Intensive Care between January 2020 and December 2022 and who were applied sepsis filters
Who cannot join
- -Patients who underwent hemodiafiltration with sepsis filter but could not be followed for 72 hours (death, etc.)
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Change in Hemogram-Derived Ratios With Sepsis Filters:A Retrospective Cohort Study in the Intensive Care Unit
Hemodiafiltration is initiated in hemodynamically unstable patients in intensive care units. In some patients, additional devices called cytokine filters or sepsis filters are added to remove inflammatory cytokines. Data obtained from hemograms, such as platelet lymphocytosis ratio, are used in the diagnosis or prognosis of many diseases. This study focuses on the change in hemogram rates in patients who received hemofiltration and sepsis filters.
- Conditions
- Platelet Abnormality, Renal Failure, Immune System Disorder
- Medical subject headings
- Blood Platelet Disorders, Renal Insufficiency, Immune System Diseases
What is being measured
The primary outcome is the main question the study is designed to answer.
Platelet lymphocyte ratio change
Change in platelet lymphocyte ratio measured from hemogram at the beginning (day 0) and the ratio calculated from the sample taken on day 3 in patients undergoing hemodiafiltration with sepsis filter
Measured: up to 72 hours
Secondary outcomes (1)
change in the other ratios derived from complete blood cell count
Changes in hemogram derivation ratios measured from the hemogram at the beginning (day 0) and the ratio calculated from the sample taken on day 3 in patients who underwent hemodiafiltration with sepsis filter
Measured: up to 72 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Apr 2025
- Study start1 Jan 2024
- Primary completion1 Feb 2024
- Study completion1 Feb 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Platelet AbnormalityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 92 participants (actual)
Sponsor and investigators
- Lead sponsor
- Samsun University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Erkan Bayram, Study chair, Istınye university faculity of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06948630
- Sponsor's protocol ID
- Istinye University
- Status last verified
- Apr 2025
- First submitted
- 21 Apr 2025
- Last updated
- 29 Apr 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Nassiri AA, Schneider A, Hakemi MS, Sabaghian T, Ahmadi Koomleh A, Miri MM, Entezarmahdi K, Yousefzad T, Kashani K. Scientia et Cura: Illuminating the Dark Side of CRRT for Optimal Patient Benefits. Iran J Kidney Dis. 2025 Feb 25;19(1):50-58.
PubMed 40056440Wu D, Qin H. Diagnostic and prognostic values of immunocyte ratios in patients with sepsis in the intensive care unit. J Infect Dev Ctries. 2023 Oct 31;17(10):1362-1372. doi: 10.3855/jidc.17907.
PubMed 37956370
Study at a glance
From the registry record, last updated by the sponsor on 29 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Change in Hemogram-Derived Ratios With Sepsis Filters:A Retrospective Cohort Study in the Intensive Care Unit
- ClinicalTrials.gov ID
- NCT06948630
- Acronym / sponsor ID
- Istinye University
- Conditions
- Platelet Abnormality, Renal Failure, Immune System Disorder
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 92 participants (actual)
- Lead sponsor
- Samsun UniversityUniversity, hospital or other
- Study start
- 1 Jan 2024 (actual)
- Primary completion
- 1 Feb 2024 (actual)
- Study completion
- 1 Feb 2024 (actual)
- First posted
- 29 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Hemodiafiltration is initiated in hemodynamically unstable patients in intensive care units. In some patients, additional devices called cytokine filters or sepsis filters are added to remove inflammatory cytokines. Data obtained from hemograms, such as platelet lymphocytosis ratio, are used in the diagnosis or prognosis of many diseases. This study focuses on the change in hemogram rates in patients who received hemofiltration and sepsis filters.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Hemodiafiltration is started on patients in intensive care units. This study focuses on the change in hemogram rates in patients who underwent hemofiltration and had sepsis filters placed.
Key inclusion criteria (1 listed)
- Data of patients who were monitored in the Intensive Care between January 2020 and December 2022 and who were applied sepsis filters
Key exclusion criteria (1 listed)
- -Patients who underwent hemodiafiltration with sepsis filter but could not be followed for 72 hours (death, etc.)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Platelet lymphocyte ratio change
Time frame: up to 72 hours
Change in platelet lymphocyte ratio measured from hemogram at the beginning (day 0) and the ratio calculated from the sample taken on day 3 in patients undergoing hemodiafiltration with sepsis filter
1 secondary outcome
change in the other ratios derived from complete blood cell count
Time frame: up to 72 hours
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Apr 2025.
- Background: PubMed 40056440Nassiri AA, Schneider A, Hakemi MS, Sabaghian T, Ahmadi Koomleh A, Miri MM, Entezarmahdi K, Yousefzad T, Kashani K. Scientia et Cura: Illuminating the Dark Side of CRRT for Optimal Patient Benefits. Iran J Kidney Dis. 2025 Feb 25;19(1):50-58.
- Results publication: PubMed 37956370Wu D, Qin H. Diagnostic and prognostic values of immunocyte ratios in patients with sepsis in the intensive care unit. J Infect Dev Ctries. 2023 Oct 31;17(10):1362-1372. doi: 10.3855/jidc.17907.
- Individual participant dataSharing planned: No
Related trials for Platelet Abnormality
RecruitingObservational study
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Hematologic Malignancies, Inherited Disorders of Metabolism
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Erkan Bayram study chair
Istınye university faculity of Medicine
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Platelet Abnormality and Renal Failure, run by Samsun University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Platelet lymphocyte ratio change (time frame: up to 72 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06948630, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Apr 2025; AzTrials last refreshed its copy on 28 Oct 2026.